SEC Form 4 · accession 0001144204-16-128079
Harvard Apparatus Regenerative Technology, Inc. · HRGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harout DerSimonian
Officer — Chief Scientific Officer
Period of report
Oct 12, 2016
Accepted (ET)
Oct 14, 2016 · 8:00 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001563665
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 12, 2016 | P | 10,000 | $0.91 | A | 10,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.90 to $0.91, inclusive. The reporting person hereby undertakes to provide to Biostage, Inc., any security holder of Biostage, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4.
Remarks
This form has been signed under power of attorney.